Zeteo Biomedical receives NIH Award to develop a universal nasal flu vaccine in collaboration with the Iowa State University Nanovaccine Institute
Vaccines that can be quickly manufactured, deployed and self-administered at global scale volumes is crucial to protect global populations against pandemic virus threats AUSTIN, TX – 20 May 2020 –(pr.com)-- Zeteo Biomedical LLC, Inc., a privately held, medical device...
Zeteo’s patient-centric delivery systems are designed for quick manufacturing to facilitate rapid deployment of drugs and vaccines to global populations AUSTIN, TX – 14 May 2020 --(PR.com) – Zeteo Biomedical LLC announced today the availability of ZEOx1 Orion™ nasal...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
The Nanovaccine Institute is a consortium of 70 researchers at 20 universities, research institutes, national laboratories, and companies, coordinated by Iowa State University. Our research is a transdisciplinary merger of expertise in immunology, nanotechnology, materials science, microbiology, neuroscience, cancer biology, gerontology, clinical science, and social science. We are developing nanovaccines and nanotherapeutics for respiratory infections, neural disorders, tropical diseases, cancer, aging, and veterinary diseases.